Ribonova
Private Company
Funding information not available
Overview
RiboNova is a preclinical-stage biotech founded in 2018, targeting rare diseases through a novel platform focused on transfer RNA biology. The company's lead program, R007, is a Phase 2-ready small molecule for all forms of genetically-confirmed mitochondrial disease, addressing a significant unmet need in a patient population of approximately 75,000 in the U.S. Backed by venture capital and anchored at a prominent research institute, RiboNova is positioned to advance its pipeline while exploring broader applications of its tRNA-targeting platform for other diseases.
Technology Platform
Proprietary drug discovery platform targeting transfer RNA (tRNA) to develop precision medicines for mitochondrial and other diseases.
Opportunities
Risk Factors
Competitive Landscape
The mitochondrial disease therapeutic landscape lacks approved disease-modifying drugs, but includes several companies exploring gene therapy, enzyme replacement, and other small molecule approaches. RiboNova's tRNA-focused mechanism is a differentiating but unvalidated strategy, placing it in a race to demonstrate clinical proof-of-concept against other emerging modalities.